Management of antipsychotic treatment discontinuation and interruptions using model-based simulations

References

• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psych20041612 Suppl156
   PubMed Web of Science ®Google Scholar
• KaneJMTreatment adherence and long-term outcomesCNS Spectrums20071210 Suppl 17212617934386
   PubMed Web of Science ®Google Scholar
• MarshallMRathboneJEarly intervention for psychosisCochrane Database Syst Rev20066CD004718
   Google Scholar
• BhanjiHChouinardGMargoleseHCA review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophreniaEur Neuropsychopharmacol200414879215013023
   PubMed Web of Science ®Google Scholar
• MasandPSRocaMTurnerMSKaneJMPartial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care CompanionJ Clin Psychiatry200911147154
   Google Scholar
• WeidenPJZygmuntAThe road back: working with the severely mentally ill. Medication noncompliance in schizophreniaJ Pract Psychiatr Behav Health19973106110
   Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry201116860360921362741
   PubMed Web of Science ®Google Scholar
• MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry20088323918447935
   PubMed Web of Science ®Google Scholar
• SchoolerNRRelapse and rehospitalization: comparing oral and depot antipsychoticsJ Clin Psychiatry200364 Suppl 16141714680414
   PubMed Web of Science ®Google Scholar
• KozmaCMSlatonTDiraniRGopalSFastenauJHoughDChanges in schizophrenia-related health care resource utilization among patients receiving paliperidone palmitate: results of a 52-week clinical trialCurr Med Res Opin2011271603161121696265
   PubMed Web of Science ®Google Scholar
• SubotnikKLNuechterleinKHVenturaJRisperidone non-adherence and return of positive symptoms in the early course of schizophreniaAm J Psychiatry201116828629221205805
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv20045588689115292538
   PubMed Web of Science ®Google Scholar
• KeithSJKaneJMPartial compliance and patient consequences in schizophrenia: our patients can do betterJ Clin Psychiatry2003641308131514658944
   PubMed Web of Science ®Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry20091956367
   Web of Science ®Google Scholar
• RobinsonDGMedication adherence and relapse in recent-onset psychosisAm J Psychiatry201116824024221368304
   PubMed Web of Science ®Google Scholar
• ZhuBAscher-SvanumHShiLFariesDMontgomeryWMarderSRTime to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaPsychiatr Serv20085931531718308914
   PubMed Web of Science ®Google Scholar
• KramerMSimpsonGMaciulisVPaliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychopharmacol20072761417224706
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarUPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res201011610711719959339
   PubMed Web of Science ®Google Scholar
• MarkowitzMTurkozIFuDJPost hoc comparative effectiveness study of paliperidone palmitate vs paliperidone ER: an indirect comparison from placebo-controlled relapse prevention studiesPresented at the American College of Neuropsychopharmacology 49th Annual MeetingDecember 5–9, 2010Miami Beach, FL
   Google Scholar
• WilsonWHA visual guide to expected blood levels of long-acting injectable risperidone in clinical practiceJ Psychiatr Pract20041039340115583522
   PubMedGoogle Scholar
• Risperdal^® (risperidone, full prescribing information)Titusville, FLJanssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc2011
   Google Scholar
• Invega^® (paliperidone, full prescribing information)Titusville, FLJanssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc2011
   Google Scholar
• BoomSTalluriKJanssensLSingle- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended releaseJ Clin Pharmacol2009491318133019713555
   PubMed Web of Science ®Google Scholar
• CirincioneBRedmanMFiedler-KelleyJLudwigEVermeulenAPopulation pharmacokinetics of paliperidone ER in healthy subjects and patients with schizophreniaClin Pharmacol Ther200781S19
   PubMed Web of Science ®Google Scholar
• ThyssenAVermeulenAFuseauEFabreMAMannaertEPopulation pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disordersClin Pharmacokinet20104946547820528007
   PubMed Web of Science ®Google Scholar
• Risperdal^® Consta^® (risperidone, full prescribing information.)Titusville, FLJanssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc2011
   Google Scholar
• GefvertOErikssonBPerssonPPharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal® Consta®) in patients with schizophreniaInt J Neuropsychopharmacol20058273615710053
   PubMed Web of Science ®Google Scholar
• SamtaniAVermeulenAStuyckensKPopulation pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly long-acting formulation of atypical antipsychoticClin Pharmacokinet20094858560019725593
   PubMed Web of Science ®Google Scholar
• Invega^® Sustenna^® (paliperidone palmitate) extended-release injectable suspension prescribing informationTitusville, NJJanssen, Division of Ortho-McNeil-Janssen Pharmaceuticals Inc2011
   Google Scholar
• CletonARossenuSHoughDAssessment of the dose proportionality of paliperidone palmitate 25, 50, 100, and 150 mg eq. A new long-acting injectable antipsychotic following administration in the deltoid or gluteal musclesClin Pharmacol Ther200883S31
   Web of Science ®Google Scholar
• BisharaDOnce-monthly paliperidone injection for the treatment of schizophreniaNeuropsychiatr Dis Treat2010656157220856919
   PubMed Web of Science ®Google Scholar
• EerdekensMKarcherKRemmerieBPharmacokinetics and tolerability of long-acting injectable risperidone in schizophreniaSchizophr Res2004709110015246468
   PubMed Web of Science ®Google Scholar
• Product monographInvega^® Sustenna^® paliperidone palmitate prolonged-release injectable suspensionToronto, OntarioJanssen-Ortho Inc2010
   Google Scholar
• SamtaniMNGopalSGassmann-MayerCAlphsLPalumboJMDosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modeling and clinical trial dataCNS Drugs20112582984521936586
   PubMed Web of Science ®Google Scholar
• SheehanJJReillyKRFuDJAlphsLComparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalentsPoster 126 presented at 23rd Annual US Psychiatric and Mental Health Congress Conference and ExhibitionNovember 18–21, 2010Orlando, FL
   Google Scholar